Platelets are often described in simple terms as small anucleate cells that mediate hemostasis, but studies over more than half a century have shown that circulating platelets are heterogeneous in size, density, age, and functional responses. These subtypes not only contribute to normal hemostasis but also play pivotal roles in the pathogenesis of diverse diseases, including cardiovascular, inflammatory, and malignant disorders. Accumulating evidence indicates that alterations in specific platelet subtypes are closely linked to disease onset, progression, and severity, underscoring their importance as both biomarkers and potential therapeutic targets. Current clinical assessments of platelet status rely primarily on platelet count and mean platelet volume (MPV) as part of routine complete blood count analysis. However, these global measures often fail to capture differences in platelet subtypes, which may remain undetected despite their significant contribution to disease pathology. This gap highlights the necessity of moving beyond conventional metrics toward a more nuanced understanding of platelet heterogeneity and its clinical implications. In this review, we discuss the diversity of platelet subpopulations and their roles in health and disease, emphasizing how specific subsets contribute to divergent pathological mechanisms. We also highlight emerging strategies that target defined platelet subpopulations, illustrating how this knowledge could pave the way for more precise diagnostic and therapeutic approaches.
Tumor-associated platelets (TAP), which are reprogrammed by tumor-derived signals to acquire immunosuppressive properties, represent an emerging mechanism of immune evasion in triple-negative breast cancer (TNBC). Although immune checkpoint inhibitors have shown promise, their efficacy is frequently limited by T-cell exhaustion and therapeutic resistance. In this study, we demonstrate that TAPs, unlike healthy circulating platelets, induce T-cell dysfunction through platelet-derived P-selectin, which engages P-selectin glycoprotein ligand 1 (PSGL-1) on T cells. This interaction promotes immunosuppressive signaling, driving T-cell exhaustion and impairing antitumor cytotoxicity. Using in vitro coculture systems and in vivo TNBC models, we show that disruption of the P-selectin–PSGL-1 axis, including pharmacologic blockade with the FDA-approved anti–P-selectin antibody crizanlizumab, restores T-cell function and enhances responsiveness to immune checkpoint blockade. Notably, PSGL-1, traditionally recognized for its role in leukocyte trafficking and immune regulation, is co-opted by TAPs to suppress T-cell activity, revealing a mechanism of platelet-mediated immune modulation. These findings establish TAPs as active regulators of antitumor immunity and identify the P-selectin–PSGL-1 axis as a therapeutically actionable target to overcome resistance to immunotherapy in TNBC. Significance: Tumor-associated platelets help TNBCs evade immune attack by suppressing T-cell function through P-selectin signaling. Blocking this pathway with crizanlizumab restores antitumor immunity and enhances response to immunotherapy, identifying a promising new combination treatment strategy for patients with this aggressive form of breast cancer.